Abstract
The incidence of malignant lymphomas is significantly higher in patients who have congenital or acquired immunodeficiencies. Although there are some differences between these immunodeficiency-associated lymphoproliferative disorders (lALD), they share several features: a tendency to present in extranodal sites, particularly the central nervous system and gastrointestinal tract, rapid clinical progression when untreated, diffuse large cell histology, B-cell origin and association with the Epstein-Barr virus (EBV). In the presence of disturbed T-cell function EBV may induce not only prolonged proliferation but also transformation of B-cells. In patients with primary, congenital immunodeficiency the incidence of lALD ranges from 0.7% for patients with X-linked agammaglobulinemia to 12–15% in patients with ataxia telangiectasia. In patients with post-transplant lymphoproliferative disorders (PT-LPD) the incidence varies from 0.5% after bone marrow transplantation to 10% after heart-lung transplantation. PT-LPD are often characterized by a polymorphic cell population. Recent studies identified three categories: plasmacytic hyperplasia, poly morphic lymphoproliferation and B-cell non-Hodgkin’s lymphoma (NHL). The plasmacytic hyperplasias are of polyclonal composition, while polymorphic lymphoproliferations and NHL are monoclonal. The precise risk of lymphoma development in HIV infection is not defined, but estimates suggest a prevalence of 3–4%. HIV-related NHLs are divisible by site of manifestation into systemic, primary central nervous system and body-cavity lymphomas, and by pathology into Burkitfs and Burkitt’s-like lymphoma, and diffuse large cell lymphoma (DLCL). In about 90% of cases these lymphomas are of monoclonal B-cell composition. Recent experiences suggest a link between therapy with immunosuppressive drugs (methotrexate, azathioprine, cyclophospamide, etc.) and development of lALD, best supported by the increased rate of lALD in patients with rheumatoid arthritis who receive methotrexate therapy. The occurrence of lALD demonstrates the importance of competent immunosurveillance in the development of lymphoid neoplasias, which may have therapeutic relevance too.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ehrlich P (1957) Über den jetzigen Stand der Karzinomforschung. In: The collected papers of Paul Ehrlich, vol 2, p 550
Prang NS, Hornef MW, Jager M, et al (1997) Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lympho cytes during infectious mononucleosis and in the normal carrier state. Blood 5:2114–2116
Rosen FS, Cooper MD, Wedgwood RJ (1984) The primary immunodeficiencie N Engl J Med 311:235–242
Filipovich AH, Shapiro R, Robison L, et al (1990) Lymphoproliferative disor-ders associated with immunodeficiency. In: Margrath IT (ed) The non-Hodg-kin’s lymphomas. Edward Arnold, London, pp 135–154
Elenitoba-Johnson KSJ, Jaffe ESI (1997) Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 1:35–47
Knowles DM (1999) Immunodeficiency-associated lymphoproliferative disorders Mod Pathol 2:200–217
Seidemann K, Tiemann M, Henze G, et al (1999) Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 6:536–544
Penn I, Hammond W, Brettschneider L, Starzl TE (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1:106–112
Young L, Alfieri C, Hennessy K, et al (1989) Expression of Epstein-Barr virus trans format ion-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080–1085
Knowles DM, Cesarmen E, Chadburn A, Frizzera G, et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565
Starzl TE, Nalesnik MA, Portier KA, et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583–587
Oertel SH, Ruhnke M, Anagnostopoulos I, et al (1999) Treatment of Epstein-Barr virus-induced post-transplant lymphoproliferative disorder (PT-LPD) with Foscarnet alone in an adult after simultaneous heart and renal translantation. Transplant, pp 765–767
Faller DV, Hermine O, Small T, et al (2000) Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus associated lymphomas. Blood 11:577
Oertel SH, Anagnostopoulos I, Bechstein WO, et al (2000) Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with PT-LPD after solid organ transplantation? Transplantation 3:430–432
Rooney CM, Smith CA, Ng CY, et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogenic transplant recipients. Blood 5:1549–1555
Haddad E, Pazesny S, Leblond V, et al (2001) Treatment of B-Iymphoproliferative disorders with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial Blood 6:1590–1597
Garrett TJ, Chadburn A, Knowles DM, et al (1993) Post-transplant lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 72:2782–2785
Cote TR, Biggar RJ, Rosenberg PS, et al (1997) Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. Int I Cancer 73:645–650
Knowles DM (1997) The molecular pathology of AIDS-related non-Hodgkin’s lymphoma. Semin Diagn Pathol 14:67–82
Tirelli, M, Spina U, laeger E, Higra PL, Blanc AM, Liberati A, Benci JA (2001) Sparano. Infusional CDE with rituximab for the treatment of HIV-associated NHL: preliminary results of a phase I/II study. Ree Results Cancer Res, p 159
Schneider U, Ruhnke M, Delecluse Hf, et al (2000) Regression of Epstein-Barr virus associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. Ann Hematol 79:214–216
Kamel OW (1997) Iatrogenic lymphoproliferative disorders in nontransplantational settings. Semin Diagn Pathol 1:27–34
Thomasen RW, Graig EE, Banks PM, et al (1996) Epstein-Barr virus and lymphoproliferation in methotrexate treated rheumatoid arthritis. Mod Pathol 9:261–266
Kurzrock R, Strom SS, Estey E, et al (1997) Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 5:1803–1810
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Oertel, S.H., Riess, H. (2002). Immunosurveillance, Immunodeficiency and Lymphoproliferations. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive